CMSC 2022

Safety and Efficacy of Evobrutinib, a Bruton’s Tyrosine Kinase Inhibitor, in Relapsing Multiple Sclerosis over 2.5 years of the Open-Label Extension to a phase 2 Trial

Montalban | Oral #DMT02

Effects of Evobrutinib, a Bruton's Tyrosine Kinase Inhibitor, on Slowly Expanding Lesions: An Emerging Imaging Marker of Chronic Tissue Loss in Multiple Sclerosis

Arnold | Poster #DMT17

Can a Shared Decision-Making Tool Improve Multiple Sclerosis DMT Utilization? The MS-SUPPORT Decision Aid

Col |Poster #8367

Exploratory Analysis of Serum GDF-15 Levels in Patients Receiving Subcutaneous Interferon β-1a in the REFLEX Trial

Coray | Poster #DMT39

Post-Approval Safety of Subcutaneous Interferon β-1a in the Treatment of Multiple Sclerosis, with Particular Reference to Respiratory Viral Infections

Freedman |Poster #DMT40

Development and Interrelation of Spatiotemporal Patterns of Brain Atrophy and Lesions During 5 Years’ Treatment with Subcutaneous Interferon Beta-1a in Patients with a First Clinical Demyelinating Event in the REFLEX/ION Study

Gentile | Poster #DMT21

Long-Term Efficacy for Patients Receiving Cladribine Tablets (3.5 mg/kg over 2 Years) in CLARITY/CLARITY Extension: A Post Hoc Analysis of CLASSIC-MS

Giovannoni |Poster #LB

Patient Characteristics and Treatment Patterns Prior to Initiating Cladribine Tablets: a US Retrospective Commercial Claims Analysis

Kozma | Poster #DMT15

Evobrutinib Significantly Reduces Relapses and Magnetic Resonance Imaging Outcomes in Patients with Multiple Sclerosis: Association with Baseline Neurofilament Light Chain Levels

Kuhle | Poster #DMT18

Development and Interrelation of Whole-Brain Atrophy and Lesion Volume During 5 Years’ Treatment with Subcutaneous Interferon Beta-1a in Patients with a First Clinical Demyelinating Event in the REFLEX/ION Study

Mattiesing | Poster #DMT22

Quality of Life and Treatment Outcomes Among People with Multiple Sclerosis Before and During the COVID-19 Pandemic

Nicholas | Poster #QOL16

Work Productivity Among People with Multiple Sclerosis Before and During the COVID-19 Pandemic

Nicholas | Poster #QOL17

Cladribine Tablets After Treatment with Natalizumab (CLADRINA) Trial - Interim Analyses

Sguigna | Poster #DMT31

CLadribine Tablets: Collaborative Study to Evaluate the Impact On CNS BiomarKers in Multiple Sclerosis (CLOCK-MS) – Current Baseline Characteristics

Wu | Poster # DMT29